Our Story

Shanton Pharma is a clinical-stage biotech company founded in 2016, with a research focus on the unmet needs associated with gout, hyperuricemia, and pruritus. Our team focuses its resources on these important therapeutic areas through advanced and innovative drug research and developmental approaches.

The Shanton team has researched hyperuricemia and gout for many years, resulting in the development  of our lead product, SAP-001 for the treatment of refractory and/or tophaceous gout and the prevention  of asymptomatic hyperuricemia developing into gout. SAP-001 has been shown in  clinical studies to be safe and effective in patients with symptomatic hyperuricemia and gout. SAP-001 is  a convenient oral monotherapy that can bring blood uric acid below 3 mg/dL, and by reducing the dose,  maintain uric acid levels between 3-5 mg/dL for a long period of time, dissolving tophi and preventing  crystals from forming again. 

Our Leadership

Senior Management
Scientific Advisors
Bing Li, Ph.D.
Chief Executive Officer

Dr. Li carries more than 25 years of experience in healthcare, and is highly regarded as a strong business leader with extensive experience in creating/turning around businesses in pharma and biotech industries.

Dr. Li’s previous positions include the founding CEO of LianBio (Nasdaq: LIAN), CEO of China Biologic Products (Nasdaq: CBPO), leader of Fosun global healthcare investment teams, leader of Warburg Pincus pharma/biotech practice in China, and management positions at GSK China and Eli Lilly.

Dr. Li received a Ph.D. in Biology from University of Rochester, an M.B.A. from Kellogg Management School and B.S. from Fudan University.

Read More
Pieter de Ridder, MBA
VP of Business Development

Pieter de Ridder is an experienced business development executive with a track record in the international biopharma industry. He has worked for global pharma (Organon, Diosynth) as well as high-growth emerging biotech companies (Synthon) in roles of increasing responsibility. He has negotiated dozens of deals for biotechs with large and midsized pharma, planned impactful product launches, and managed successful alliances. As the founder of a management consultancy, he assisted life sciences startups by writing impactful business plans and negotiating their first deals.

Mr. De Ridder earned his bachelor’s degree from Avans Hogeschool in Breda, the Netherlands, and an executive MBA from Duke University – The Fuqua School of Business in Durham, NC.

Read More
Koji Matsuyama, Ph.D.

Dr. Matsuyama is the Founder of Shanton Pharma and has been engaged in researching and developing innovative drugs in the pharmaceutical industry for more than 20 years.

Dr. Matsuyama received a Ph.D. in Biology from the University of Tokyo.

Read More
Qian Zhang
Project Manager

Qian Zhang is the Project Manager of Shanton Pharma and has been engaged in preclinical and non-clinical coordination management, research and development of innovative drugs in the pharmaceutical industry for more than 14 years.

Read More
Celina Cabale-Scholl, Ph.D.
VP of Clinical Operations

Celina Cabale-Scholl has over 18 years of industry experience in both small and large companies. Her experience spans infectious disease, rare disease, CNS/neurology and cardiometabolic therapeutic areas.
Ms. Cabale-Scholl came from other biopharma companies such as Novartis, Vertex and Ovid with experience in Development and Operations, which included Project Team representation for Clinical, and oversight of multiple clinical and functional vendors.

Ms. Cabale-Scholl received a doctorate degree from MGHIHP.

Read More

Our Impact

At Shanton Pharma our mission is to address the global clinical unmet needs associated with gout, hyperuricemia, and pruritus.
Our ultimate goal for gout is to completely eliminate the disease.

We strive to bring innovative new medicines to patients and the medical communities we serve,
by focusing on the development and commercialization of our core products.